Vericel to Present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present an overview of the company at the Canaccord Genuity Virtual Musculoskeletal Conference.

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present an overview of the company at the Canaccord Genuity Virtual Musculoskeletal Conference. The presentation is scheduled for May 20, 2021, at 9:30 a.m. Eastern Time. Interested parties can access a live webcast through the Investor Relations section of the Vericel website.

Vericel specializes in advanced therapies for sports medicine and severe burn care, offering innovative products such as MACI® and Epicel®.

Argus Session date unavailable

+1.40% session move Open Argus

Details

News Market Reaction – VCEL

The recorded move for VCEL in the trading session of this news was +1.40%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Canaccord Genuity Virtual Musculoskeletal Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, May 20, 2021, at 9:30 a.m. Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date and time of the Vericel presentation at the Canaccord Genuity Conference?

The Vericel presentation is scheduled for May 20, 2021, at 9:30 a.m. Eastern Time.

Who will present at the Canaccord Genuity Virtual Musculoskeletal Conference?

Nick Colangelo, President and CEO of Vericel Corporation, will present at the conference.

How can I watch the Vericel presentation live?

You can access the live webcast of the Vericel presentation through the Investor Relations section of their website.

What are the main products offered by Vericel Corporation?

Vericel offers MACI® for cartilage repair and Epicel® for skin replacement in burn patients.

What is the stock symbol for Vericel Corporation?

The stock symbol for Vericel Corporation is VCEL.